MetLife director granted 294 dividend shares

A MetLife non-management director received a small stock grant tied to dividend reinvestment on deferred shares, modestly increasing his direct holdings.

Rhea-AI Filing Summary

METLIFE INC (MET) reported that director William E. Kennard acquired 294 shares of common stock on September 8, 2026 as a grant related to imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors at a reference value of $95.50 per share. Following this award, he holds 47,704 shares directly and 10 shares indirectly through the MetLife Policyholder Trust.

Insider Trade Summary

Grant/Award: 294 shares

Grant/Award 2 txns

Insider Kennard William E

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	294	$95.50	$28K
holding	Common Stock F2	--	--	--

Holdings After Transaction: Common Stock — 47,704 shares (Direct); Common Stock — 10 shares (Indirect, By the MetLife Policyholder Trust)

Footnotes (2)

1. F1. Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred.
2. F2. Shares held in trust under the MetLife Policyholder Trust established to hold shares of common stock allocated to eligible policyholders of Metropolitan Life Insurance Company, a wholly-owned subsidiary of MetLife, Inc.

Key Figures

Shares acquired: 294 shares Reference share value: $95.50 per share Direct holdings after transaction: 47,704 shares +2 more

5 metrics

Shares acquired 294 shares Grant/award acquisition on September 8, 2026

Reference share value $95.50 per share Attributed value for the 294-share grant on September 8, 2026

Direct holdings after transaction 47,704 shares Common stock directly owned by William E. Kennard after the grant

Indirect holdings after transaction 10 shares Common stock held indirectly via the MetLife Policyholder Trust

Transaction date September 8, 2026 Date of grant/award acquisition and holdings report

Key Terms

MetLife Deferred Compensation Plan for Non-Management Directors, deferred shares, MetLife Policyholder Trust

3 terms

MetLife Deferred Compensation Plan for Non-Management Directors financial

"Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors"

deferred shares financial

"Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred"

Deferred shares are a class of stock whose economic benefits or certain shareholder rights are delayed or paid later than ordinary shares—for example, dividends may be paid only after other shareholders receive theirs, or voting or redemption rights may be postponed. For investors, that timing difference matters because deferred shares typically offer lower near-term income and different risk, affecting expected returns, priority in payouts, and the share’s market value; think of them like a delayed paycheck compared with a regular salary.

MetLife Policyholder Trust financial

"Shares held in trust under the MetLife Policyholder Trust established to hold shares"

FAQ

What insider transaction did MET (MetLife Inc.) disclose for William E. Kennard?

MetLife disclosed that director William E. Kennard received a grant of 294 common shares on September 8, 2026, reflecting imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors.

At what value were the new MET shares attributed in William E. Kennard’s Form 4?

The 294 MetLife common shares were attributed a value of $95.50 per share, as reported for the grant tied to dividend reinvestment on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors.

How many MET shares does William E. Kennard hold after this reported transaction?

After the September 8, 2026 award, William E. Kennard holds 47,704 MetLife common shares directly and 10 shares indirectly through the MetLife Policyholder Trust, as reported in the Form 4 filing.

What is the source of the additional MET shares reported for William E. Kennard?

The additional 294 MetLife shares arise from imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors, according to the Form 4 footnote.

How are some of William E. Kennard’s MET shares held indirectly?

William E. Kennard has 10 MetLife shares held in trust under the MetLife Policyholder Trust, which holds common stock allocated to eligible policyholders of Metropolitan Life Insurance Company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/10/2026 - 04:03 PM Accepted by SEC EDGAR 09/10/2026 - 04:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kennard William E

(Last) (First) (Middle)

METLIFE, INC.

200 PARK AVENUE

(Street)

NEW YORK NEW YORK 10166

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
METLIFE INC [ MET ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/08/2026		A(1)		294	A	$95.5	47,704	D
Common Stock								10	I	By the MetLife Policyholder Trust(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred.

2. Shares held in trust under the MetLife Policyholder Trust established to hold shares of common stock allocated to eligible policyholders of Metropolitan Life Insurance Company, a wholly-owned subsidiary of MetLife, Inc.

Remarks:

	/s/ Morgan Keehner-Jones Mayes, Attorney-in-fact	09/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)